^
    COLARIS® assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine (endometrial) cancer. COLARIS® detects mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes. These are the gene mutations that are responsible for the vast majority of Lynch Syndrome and MYH-associated polyposis (MAP) cases.
    Cancer:
    Colorectal Cancer, Endometrial Cancer
    Gene:
    EPCAM (Epithelial cell adhesion molecule), MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MUTYH (MutY homolog), PMS2 (PMS1 protein homolog 2)
    Method:
    Comparative Genomic Hybridization (CGH)